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Why 88% of US military veterans with HCV are not treated
Legislation should be passed allowing veterans with HCV to
prequalify for their choice of Medicaid or Medicare so that they
can obtain antiviral therapy in the private sector. Since Dr. Kizer
is no longer in charge of the VA, it is very clear that the VA is not
going to treat very many of them.
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Letters to the EditorTo the Editor:
The article in the February issue of the Journal of Hepatology
reported that less than 12% of American military veterans identi-
ﬁed with HCV were treated with antiviral therapy [1]. The Veter-
ans Administration does not want to spend adequate funds to
cure patients with hepatitis C. Dr. Kenneth Kizer, Under Secretary
for Health in the US Department of Veterans Affairs (VA), gave
HCV a high priority but unfortunately he left the VA in 1999. Sub-
sequent leadership has not shown enthusiasm for treating HCV.
The Director of Pharmacy and the Chief of Staff at my local VA
hospital told me that I spent too much money treating HCV. Boce-
previr and telaprevir are both on the hospital formulary but tela-
previr prescriptions are routinely denied because it is more
expensive. Patients must jump multiple hurdles before qualifying
for antiviral therapy. No one would refuse to give coronary artery
stents or bypass grafts to a veteran who smokes but veterans who
do not completely abstain from alcohol for three months are
refused antiviral therapy. In spite of difﬁculties, 585 of 1372
(43%) HCV RNA positive patients received antiviral therapy
between 1998 and 2010 at our local VA hospital; 226 of 583 trea-
ted (39%) achieved SVR [2]. 36% of deaths were from HCC or liver
failure. Veterans with sustained viral response had substantially
improved survival. Effective antiviral therapy improves prognosis
[3,4]. Less than 2% of Americans die from liver disease, but more
than one third of veterans with HCV die prematurely from com-
plications of cirrhosis [2,5]. According to a 2010 national VA
report, deaths in veterans with HCV have more than tripled,
‘‘Between 2000 and 2008, the annual number of all cause deaths
recorded for Veterans with chronic HCV rose from 1259 (1129
per 100,000 in VHA care) to 5967 (4049 per 100,000 in VHA care),
respectively’’ [6].924 Journal of Hepatology 2012 vol. 57 j 921–934
